In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MultiCell Technologies, Inc.

http://www.multicelltech.com/

Latest From MultiCell Technologies, Inc.

Wockhardt’s UK Business Grows But Other Markets Underperform

Wockhardt has seen a good financial fourth quarter and full year for its UK business, which contributed 41% of the company’s global revenue in Q4 FY21 and 37% to its global revenue for the financial year thanks to its COVID-19 vaccine business. However, the company’s US, India, Ireland and emerging markets businesses delivered a weak fourth quarter.

Sales & Earnings United Kingdom

UK As New Global Base, Serum Institute Mulls Acquisition Or Greenfield Unit

After setting up a sales base in the UK, Serum Institute could consider an acquisition in Europe or investment in an Oxford facility as it ties up production for its multiple COVID-19 vaccines. Is Wockhardt’s Wrexham facility an option?

Commercial Coronavirus COVID-19

Alvogen Companies Donate To Support COVID Vaccines

Alvogen and sister company Alvotech have donated to UNICEF to support vaccine supply to over 90 low-and-middle-income countries, while Hikma has also made a multi-million-dollar donation. India’s Dr Reddy’s is moving ahead with the Sputnik V vaccine, while AstraZeneca is partnering with Insud Pharma on its vaccine in Spain. Meanwhile, the UK government has extended its vaccination contract with Wockhardt.

International Coronavirus COVID-19

Finance Watch: $2.2bn In New Funding Sources In February, So Far

Private Company Edition: New capital for health care and life science innovations include a fund for royalty deals, additional anti-infective funding, early-stage money and public health-focused cash. Also, Day One reveals a $130m series B venture round and Notch closes an $85m series A round.

Financing Innovation
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register